CN112274577A - 包含芭蕉属物种发酵物的组合物的用途及益生质组合物 - Google Patents
包含芭蕉属物种发酵物的组合物的用途及益生质组合物 Download PDFInfo
- Publication number
- CN112274577A CN112274577A CN201910714710.3A CN201910714710A CN112274577A CN 112274577 A CN112274577 A CN 112274577A CN 201910714710 A CN201910714710 A CN 201910714710A CN 112274577 A CN112274577 A CN 112274577A
- Authority
- CN
- China
- Prior art keywords
- composition
- musa
- oligosaccharide
- growth
- fermentation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 66
- 235000013406 prebiotics Nutrition 0.000 title claims abstract description 20
- 241000204931 Musa sp. Species 0.000 title claims 5
- 241000234295 Musa Species 0.000 claims abstract description 26
- 238000000855 fermentation Methods 0.000 claims abstract description 17
- 230000001737 promoting effect Effects 0.000 claims abstract description 17
- 230000004151 fermentation Effects 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical group OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 18
- 239000000832 lactitol Substances 0.000 claims description 18
- 235000010448 lactitol Nutrition 0.000 claims description 18
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 18
- 229960003451 lactitol Drugs 0.000 claims description 18
- 229920001542 oligosaccharide Polymers 0.000 claims description 17
- 150000002482 oligosaccharides Chemical class 0.000 claims description 12
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 9
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 9
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000002054 inoculum Substances 0.000 claims description 7
- 150000005846 sugar alcohols Chemical class 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 241000589220 Acetobacter Species 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 241000514285 Ekmania Species 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 241000193830 Bacillus <bacterium> Species 0.000 claims 1
- 150000002772 monosaccharides Chemical class 0.000 claims 1
- 239000006041 probiotic Substances 0.000 abstract description 43
- 235000018291 probiotics Nutrition 0.000 abstract description 43
- 230000000529 probiotic effect Effects 0.000 abstract description 36
- 210000000577 adipose tissue Anatomy 0.000 abstract description 11
- 241000702460 Akkermansia Species 0.000 abstract description 10
- 230000037396 body weight Effects 0.000 abstract description 5
- 230000000813 microbial effect Effects 0.000 abstract description 3
- 241000702462 Akkermansia muciniphila Species 0.000 description 30
- 241000894006 Bacteria Species 0.000 description 23
- 240000008790 Musa x paradisiaca Species 0.000 description 22
- 210000001035 gastrointestinal tract Anatomy 0.000 description 17
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 15
- 239000000047 product Substances 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 9
- 230000000968 intestinal effect Effects 0.000 description 9
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 6
- 238000003753 real-time PCR Methods 0.000 description 6
- 239000007621 bhi medium Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 229920001202 Inulin Polymers 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 4
- 229940029339 inulin Drugs 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- 244000283763 Acetobacter aceti Species 0.000 description 3
- 235000007847 Acetobacter aceti Nutrition 0.000 description 3
- 241000186000 Bifidobacterium Species 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 239000004386 Erythritol Substances 0.000 description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 235000019414 erythritol Nutrition 0.000 description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 3
- 229940009714 erythritol Drugs 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 239000000845 maltitol Substances 0.000 description 3
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 3
- 235000010449 maltitol Nutrition 0.000 description 3
- 229940035436 maltitol Drugs 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 229960001855 mannitol Drugs 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-amino-7-oxononanoic acid zwitterion Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 244000291473 Musa acuminata Species 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 210000002175 goblet cell Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 230000004630 mental health Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- CDVZCUKHEYPEQS-IBVPOFDWSA-N (2r,3s,4r)-2,3,4,5-tetrahydroxypentanal Chemical group OC[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@H](O)[C@@H](O)C=O CDVZCUKHEYPEQS-IBVPOFDWSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102100028183 Cytohesin-interacting protein Human genes 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 101000916686 Homo sapiens Cytohesin-interacting protein Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 235000003805 Musa ABB Group Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 235000015266 Plantago major Nutrition 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 102000008228 Toll-like receptor 2 Human genes 0.000 description 1
- 108010060888 Toll-like receptor 2 Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000009118 appropriate response Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000008556 epithelial cell proliferation Effects 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 239000009270 zilongjin Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Botany (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medical Informatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Alternative & Traditional Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
Abstract
本发明涉及微生物发酵领域,特别是关于包含芭蕉属物种发酵物的组合物的用途及益生质组合物。本发明提供一种包含芭蕉属物种发酵物的组合物用于制备促进嗜黏蛋白艾克曼菌生长的益生质组合物的用途,及一种包含芭蕉属物种发酵物的益生质组合物。该益生质组合物促进肠道内嗜黏蛋白艾克曼菌的生长,并且能降低肥胖者的体重、体脂率、腰围、及臀围。
Description
技术领域
本发明涉及微生物发酵领域,特别是关于包含芭蕉属物种发酵物的组合物的用途及益生质组合物。
背景技术
诸多医学研究显示肠道环境与身体正常机能的维持及疾病预防密切相关。肠道不仅是消化器官,而且驻扎大量免疫细胞以抵抗病原体由此侵入身体,并且密布神经分支以收集生理讯息反馈中枢神经,因此,肠道健康影响人体健康甚巨。最近十数年研究发现,肠道黏膜中居住着千种以上的肠道菌,它们与身体器官互相沟通并且给出适当反应,例如供应身体所需养分、调控肠道细胞发育、及诱导免疫系统发展,故肠道菌可谓是身体的一种必要器官。
肠道菌的构成细菌各有特定功用,当其组成因为不良生活习惯、疾病、使用抗生素等原因失去平衡,身体就可能失去健康。例如,若个人平日摄取高脂肪含量饮食,大肠中嗜吃脂肪的革兰氏阴性菌会大量增殖及产生脂多醣(lipopolysaccharides,LPS),其可透过血液循环在身体各处引起慢性发炎,最终可能导致第二型糖尿病、心血管疾病、甚至神经退化疾病与癌症等慢性病。亦有研究显示,肠道菌组成被破坏的小鼠在压力情境下的记忆力衰退。因此,维持肠道菌的组成恒定有助于维持身心健康。
目前已知有益人体健康的肠道菌除了双歧杆菌属(Bifidobacterium)与乳酸杆菌属(Lactobacillus)细菌,嗜黏蛋白艾克曼菌(Akkermansia muciniphila)亦是极具潜力的益生菌。该菌占成人肠道菌的1%至4%,是一种生长在大肠的绝对厌氧革兰氏阴性菌,可利用黏蛋白(mucin)作为唯一营养来源。艾克曼菌被报道为与醣类、脂肪代谢及肠道免疫相关。有研究发现艾克曼菌可分解黏蛋白及产生短链脂肪酸(如乙酸)以提供肠道杯状细胞(goblet cells)所需的能量,从而促进黏蛋白生成及增加肠道黏液层厚度。此外,艾克曼菌的外膜蛋白Amuc-1100被发现能活化肠道上皮细胞中类铎受体2(Toll-like receptor 2,TLR2)介导的细胞内讯号,进而促进肠道上皮细胞增生。该些艾克曼菌的作用皆有助于维持肠道屏障(gut barrier)完整性,因此能减少肠道中的有害物质进入血液,达到降低发炎反应的目的。另有研究发现,施用艾克曼菌的高脂饮食小鼠有较低的血液中脂多醣浓度,并且表现出胰岛素抗性的改善与脂肪堆积下降。
鉴于艾克曼菌对维持肠道健全乃至于身心健康的重要性,开发一种促进肠道内艾克曼菌生长的益生质组合物,实有其必要。
发明内容
缘此,本发明的一目的在提供一种包含芭蕉属物种发酵物的组合物用于制备促进嗜黏蛋白艾克曼菌生长的益生质组合物的用途。
在本发明的一实施例中,该芭蕉属物种发酵物是一芭蕉属物种果肉与水的混合物经过一嗜热链球菌(Streptococcus thermophilus)及一酿酒酵母(Saccharomycescerevisiae)的前发酵,再经过一醋酸杆菌(Acetobacter aceti)的后发酵而获得。
在本发明的一实施例中,该芭蕉属物种果肉与水的混合物是芭蕉属物种果肉与水以1∶1至1∶20的重量比混合而得;该嗜热链球菌及该酿酒酵母在前发酵中的接种量分别为0.1%至0.4%(w/v)及0.2%至0.5%(w/v),且该醋酸杆菌在后发酵中的接种量为2%至5%(w/v)。
在本发明的一实施例中,该包含芭蕉属物种发酵物的组合物进一步包含一寡糖,该寡糖是选自于木寡糖、异麦芽寡糖、及其组合。前述组合物可进一步包含一糖醇;该糖醇包括山梨糖醇、甘露糖醇、赤藓糖醇、麦芽糖醇、乳糖醇、木糖醇、及其任意组合。
在本发明的一较佳实施例中,该包含芭蕉属物种发酵物的组合物进一步包含木寡糖及乳醣醇,且该芭蕉属物种发酵物、该木寡糖、及该乳糖醇的重量比范围为3~5∶2~4∶2~4。在一最佳实施例中,该芭蕉属物种发酵物、该木寡糖、及该乳糖醇的重量比为4∶3∶3。
本发明的又一目的在提供一种促进嗜黏蛋白艾克曼菌生长的益生质组合物,包含一芭蕉属物种发酵物、一寡糖、及一糖醇,其中该寡糖是选自于木寡糖、异麦芽寡糖、及其组合。
本发明的又一目的在提供一种前述益生质组合物用于制备减少腰围的医药组合物的用途。
在本发明的一实施例中,该益生质组合物增加肥胖受试者肠道内嗜黏蛋白艾克曼菌的数量,并且降低肥胖受试者的体重、全身或躯干体脂率、腰围、及臀围。
本发明揭露有利于嗜黏蛋白艾克曼菌生长的多种益生质及其组合。该益生质组合可用于制备有效促进嗜黏蛋白艾克曼菌生长的益生质组合物,例如用作体外细菌培养的培养基添加物,或用作促进活体(如人体)肠道内嗜黏蛋白艾克曼菌增殖的益生质产品。该益生质组合物可具有粉末、颗粒、溶液、或胶囊的剂型,且可制成食品、饮品、医药品、或营养补充剂,藉由口服方式给予一个体。
由于维持人体肠道内嗜黏蛋白艾克曼菌的适当数量可以减少慢性发炎、改善醣类代谢、及抑制脂肪堆积,本发明的益生质组合物因促进嗜黏蛋白艾克曼菌的生长而具备缓解或预防代谢疾病(如糖尿病)、心血管疾病(如动脉粥样硬化)、及老化相关疾病(如失智症)的潜力。
以下将配合图式进一步说明本发明的实施方式,下述所列举的实施例是用以阐明本发明的发明特点及应用,而非以限定本发明的范围,任何熟习此技艺者,在不脱离本发明的精神和范围内,当可做些许更动与润饰,因此本发明的保护范围当视后附的申请专利范围所界定者为准。
附图说明
图1显示嗜黏蛋白艾克曼菌在含有或不含单一候选益生质的培养基中,经过厌氧培养48小时的相对菌数柱形图;
图2显示嗜黏蛋白艾克曼菌在含有或不含指定益生质组合物的培养基中,经过厌氧培养48小时后的相对菌数柱形图;
图3A显示受试者服用本发明一实施例的益生质组合物四周后,肠道内嗜黏蛋白艾克曼菌占比增加或未增加者的比例图;
图3B显示图3A中肠道内嗜黏蛋白艾克曼菌占比增加者的肠道内嗜黏蛋白艾克曼菌相对菌数柱形图;
图4显示受试者服用本发明一实施例的益生质组合物四周后的体重变化柱形图;
图5显示受试者服用本发明一实施例的益生质组合物四周后的全身体脂率变化柱形图;
图6显示受试者服用本发明一实施例的益生质组合物四周后的躯干体脂率变化柱形图;
图7显示受试者服用本发明一实施例的益生质组合物四周后的腰围变化柱形图;
图8显示受试者服用本发明一实施例的益生质组合物四周后的臀围变化柱形图。
具体实施方式
本发明提供一种包含芭蕉属物种发酵物的组合物用于制备促进嗜黏蛋白艾克曼菌生长的益生质组合物的用途。除了芭蕉属物种发酵物,该益生质组合物可进一步包含一选自于木寡糖、异麦芽寡糖、及其组合的寡糖,以及一糖醇,例如山梨糖醇、甘露糖醇、赤藓糖醇、麦芽糖醇、乳糖醇、及木糖醇。该益生质组合物较佳为包含芭蕉属物种发酵物、木寡糖、及乳糖醇,且其重量比范围较佳为3~5∶2~4∶2~4。以下实施例显示该益生质组合物中各组成物质及其组合对嗜黏蛋白艾克曼菌的生长促进效果,亦显示该益生质组合物能降低肥胖受试者的体重、全身或躯干体脂率、腰围、及臀围。
定义
本文中所使用数值为近似值,所有实验数据皆表示在20%的范围内,较佳为在10%的范围内,最佳为在5%的范围内。
本发明内使用的菌株均为现有菌株,可通过购买获得。
本文中所谓「芭蕉属物种」是指属于芭蕉属(Musa spp.)的所有物种,包括香蕉(Musa paradisiaca,又名大蕉)、小果野蕉(Musa acuminata)、及野蕉(Musa balbisiana)。
本文中所谓「木寡糖」是指包含3至10个木糖(xylose)单元的寡糖,其来源可为植物,或经微生物发酵、酵素转化、或化学合成等方式而制得。
材料与方法
芭蕉属物种发酵物的制备
芭蕉属物种富含酚类及果胶,对芭蕉属物种进行发酵将获得一组成分子更丰富的发酵物。
本文中实施例1-3所用芭蕉属物种发酵物是一香蕉发酵物,其制备方法简述如下。首先,将香蕉果肉与水依重量比1∶1至1∶20,较佳为1∶1至1∶5混合,以作为空培液。该空培液以巴斯德灭菌法处理后,接种一嗜热链球菌及一酿酒酵母,并于29至31℃进行前发酵72小时,其中该嗜热链球菌及该酿酒酵母的接种量分别为0.1%至0.4%(w/v)及0.2%至0.5%(w/v)。其后,该前发酵液再接种0.5%至1%(w/v)的醋酸杆菌,并于29至31℃进行后发酵21天,即可获得该香蕉发酵物。该香蕉发酵物可藉由如减压干燥、喷雾干燥等干燥方式制成一粉末状产物。
在一实施例中,该嗜热链球菌是自食品工业发展研究所生物资源保存及研究中心(Bioresource Collection and Research Center,BCRC)取得的嗜热链球菌BCRC 910636菌株(中国台湾专利I519644专利寄存)。在另一实施例中,该酿酒酵母是自BCRC取得的酿酒酵母BCRC 21494菌株。在又一实施例中,该醋酸杆菌是自BCRC取得的醋酸杆菌BCRC 12324菌株或BCRC 11688菌株。
寡糖、多糖及糖醇
本文中实施例所用寡糖包括木寡糖(购自山东龙力生物科技股份有限公司)、异麦芽寡糖(购自山东百龙创园生物科技股份有限公司)、及果寡糖(购自MEIJI CO.,Ltd.)。所用多糖包括菊糖(购自Cosucra Groupe Warcoing SA)。所用醣醇包括乳糖醇(购自宏伟生物科技股份有限公司)、山梨糖醇、甘露糖醇、赤藓糖醇、麦芽糖醇、及木糖醇。
细菌培养
以下实施例使用购自食品工业发展研究所生物资源保存及研究中心(Bioresource Collection and Research Center,BCRC)的嗜黏蛋白艾克曼菌(Akkermansia muciniphila,BCRC 81048)。该细菌于解冻及活化后,在37℃与厌氧条件(10%二氧化碳、10%氢气、及80%氮气)下依3%的种菌接种量预培养于BHI培养基(15g脑心灌注肉汤(BD Difco Brain Heart Infusion broth;Thermo Fischer Scientific),溶于1L去离子水,pH值约7.0)48小时,再用于益生质试验。
肠道菌数定量
采集受试者粪便,并利用粪便基因组DNA萃取套组(Stool Genomic DNAExtraction kit;图尔思生物科技公司)依厂商使用说明获得粪便基因组DNA萃取样本,其DNA浓度以Nanodrop分光亮度计(Thermo Fisher Scientific)测定。其后,基于定量聚合酶链锁反应(quantitative polymerase chain reaction,简称qPCR)测定该样本中各目标细菌的DNA含量。简言之,藉由目标细菌代表性序列及16S核糖体RNA(16S rRNA)基因的核酸引物对(表1),利用qPCR套组(KAPA CYBR FAST qPCR Kit(2X);KAPA Biosystems)在PCR反应仪(Step One Plus Real-Time PCR system;Applied Biosystems)对前述样本DNA进行qPCR,以取得各细菌代表性序列及16S rRNA基因的循环阈值(CT),其差值可用于依2-ΔCT公式计算倍数变化(fold change)。重复试验所得特定细菌代表性序列的倍数变化平均值相对于各细菌其值总和的百分比即为该菌在肠道内占比的估计值。
表1
实施例1
嗜黏蛋白艾克曼菌的益生质试验
为辨识有益于嗜黏蛋白艾克曼菌生长的营养物质,将预培养的嗜黏蛋白艾克曼菌依3%的接种量加入含有1%(w/w)候选益生质的BHI培养基,于37℃与厌氧条件下培养48小时,再将所得菌液涂布于BHI琼脂培养基并培养72小时以估计菌数。该候选益生质为木寡糖、异麦芽寡糖、乳糖醇、菊糖、果寡糖、或一香蕉发酵物。作为对照,另外将嗜黏蛋白艾克曼菌培养于不合候选益生质的BHI培养基(空白对照组)。
图1显示前述各种候选益生质对嗜黏蛋白艾克曼菌生长的影响,将空白对照组的菌数定义为100%。依据图1,相比空白对照组,使菌数有明显提升的益生质包括香蕉发酵物、木寡糖、异麦芽寡糖、及乳糖醇,其分别提升相对菌数至约283%、266%、276%、及258%。相对地,习知可促进乳酸杆菌生长的菊糖或可促进双歧杆菌生长的果寡糖无法显著提升嗜黏蛋白艾克曼菌的生长而使相对菌数保持在约110%(数据未显示)。此结果说明香蕉发酵物、木寡糖、异麦芽寡糖、及乳糖醇任一者皆可用作嗜黏蛋白艾克曼菌益生质,但并非任何有利乳酸杆菌生长的益生质(如果寡糖及菊糖)便可有效促进嗜黏蛋白艾克曼菌生长。
实施例2
促进嗜黏蛋白艾克曼菌生长的益生质组合物
为评估前述嗜黏蛋白艾克曼菌益生质的不同组合对嗜黏蛋白艾克曼菌生长的促进作用,将预培养的嗜黏蛋白艾克曼菌依3%的接种量加入含有不同益生质组合物的BHI培养基,于37℃与厌氧条件下培养48小时,再将所得菌液涂布于BHI琼脂培养基并培养72小时培养以估计菌数。各BHI培养基中的益生质组合物具有下列组成:(a)0.25%香蕉发酵物、0.25%异麦芽寡糖、0.25%木寡糖、及0.25%乳糖醇;(b)0.4%香蕉发酵物、0.3%木寡糖、及0.3%乳糖醇;(c)0.4%香蕉发酵物、0.3%异麦芽寡糖、及0.3%乳糖醇;或(d)0.4%香蕉发酵物、0.3%异麦芽寡糖、及0.3%木寡糖。作为对照,另外将嗜黏蛋白艾克曼菌培养于不含益生质的BHI培养基(空白对照组)。
图2显示前述益生质组合对嗜黏蛋白艾克曼菌生长的影响,将空白对照组的菌数定义为100%。依据图2,相比空白对照组,益生质组合物(a)、(b)、(c)、或(d)的添加显著提升嗜黏蛋白艾克曼菌的相对菌数至分别约为289%、331%、298%、及294%,且以香蕉发酵物、木寡糖、及乳糖醇的组合在重量比为3~5∶2~4∶2~4的情况下,能最有效促进嗜黏蛋白艾克曼菌的生长,即便乳醣醇在图1所示的促生长效果最低。
实施例3
益生质组合物的生理效果
本实施例探讨连续服用一含有200mg香蕉发酵物、150mg木寡糖、及150mg乳糖醇的益生质组合物胶囊对肥胖受试者的生理影响。使七位20至55岁肥胖受试者(包括男性及女性)连续四周在每日午餐后口服该益生质组合物,剂量为500mg/人/天,并于服用前及服用四周后评估该些受试者肠道内嗜黏蛋白艾克曼菌的占比,及以体组成计(TANITA BC-601FS)测量体重、全身体脂率、躯干体脂率、腰围、与臀围。所谓肥胖受试者具备以下条件:身体质量指数(BMI)大于24;男性全身体脂率大于25%,女性全身体脂率大于30%。
依据图3A及3B,服用该益生质组合物四周后,85.7%的受试者被发现肠道内嗜黏蛋白艾克曼菌的占比显著增加,且该菌菌数相对于服用前增加约80%。此结果证明本发明的益生质组合物可促进活体肠道内嗜黏蛋白艾克曼菌的生长。
依据图4至图8,相比服用前,持续四周服用益生质组合物使平均体重减少约0.39公斤,使全身体脂率平均值下降约0.4%,使躯干体脂率平均值显著下降约0.5%,使平均腰围显著减少约1.8公分,以及使平均臀围显著减少约0.5公分。此结果证实长期使用本发明的益生质组合物可改善肥胖者的体况。
综上所述,本发明揭露有利于嗜黏蛋白艾克曼菌生长的多种益生质及其组合。该益生质组合可用于制备促进嗜黏蛋白艾克曼菌生长的益生质组合物,例如用于体外细菌培养的培养基添加物,或用于促进人体肠道内嗜黏蛋白艾克曼菌增殖的益生质产品。该益生质组合物可具有粉末、颗粒、溶液、或胶囊的剂型,且可制成食品、饮品、医药品、或营养补充剂,藉由口服方式给予一个体。
Claims (10)
1.一种包含芭蕉属物种发酵物的组合物用于制备促进嗜黏蛋白艾克曼菌生长的益生质组合物的用途。
2.根据权利要求1所述的用途,其特征在于,所述芭蕉属物种发酵物是一芭蕉属物种果肉与水的混合物经过一嗜热链球菌及一酿酒酵母的前发酵,再经过一醋酸杆菌的后发酵而获得。
3.根据权利要求2所述的用途,其特征在于,所述芭蕉属物种果肉与水的混合物是芭蕉属物种果肉与水以1∶1至1∶20的重量比混合而得。
4.根据权利要求2所述的用途,其特征在于,所述嗜热链球菌及所述酿酒酵母在前发酵中的接种量分别为0.1%至0.4%(w/v)及0.2%至0.5%(w/v),且所述醋酸杆菌在后发酵中的接种量为2%至5%(w/v)。
5.根据权利要求1所述的用途,其特征在于,所述包含芭蕉属物种发酵物的组合物进一步包含一寡糖,所述寡糖是选自于木寡糖、异麦芽寡糖、及其组合。
6.根据权利要求5所述的用途,其特征在于,所述包含芭蕉属物种发酵物的组合物进一步包含一糖醇。
7.根据权利要求6所述的用途,其特征在于,所述寡糖为木寡糖,且所述糖醇为乳醣醇。
8.根据权利要求7所述的用途,其特征在于,所述芭蕉属物种发酵物、所述木寡糖、及所述乳糖醇的重量比范围为3~5∶2~4∶2~4。
9.一种促进嗜黏蛋白艾克曼菌生长的益生质组合物,包含一芭蕉属物种发酵物、一寡糖、及一糖醇,其中所述寡糖是选自于木寡糖、异麦芽寡糖、及其组合。
10.一种根据权利要求9所述的益生质组合物用于制备减少腰围的医药组合物的用途。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW108125874 | 2019-07-22 | ||
TW108125874A TWI719549B (zh) | 2019-07-22 | 2019-07-22 | 促進嗜黏蛋白艾克曼菌生長之益生質組合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112274577A true CN112274577A (zh) | 2021-01-29 |
CN112274577B CN112274577B (zh) | 2022-05-20 |
Family
ID=74187627
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910714710.3A Active CN112274577B (zh) | 2019-07-22 | 2019-08-02 | 包含芭蕉属物种发酵物的组合物的用途及益生质组合物 |
Country Status (4)
Country | Link |
---|---|
US (1) | US11478525B2 (zh) |
CN (1) | CN112274577B (zh) |
MY (1) | MY196168A (zh) |
TW (1) | TWI719549B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116548609A (zh) * | 2022-01-27 | 2023-08-08 | 大江生医股份有限公司 | 益生质组合物及其用途 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112998260A (zh) * | 2021-04-14 | 2021-06-22 | 四川省食品发酵工业研究设计院有限公司 | 一种富含高活性酶的酵素及其制备方法 |
TWI817342B (zh) * | 2022-01-27 | 2023-10-01 | 大江生醫股份有限公司 | 益生質組合物及其用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103599059A (zh) * | 2013-11-06 | 2014-02-26 | 曹书林 | 一种香蕉组合物发酵类美容美体膏 |
TW201807193A (zh) * | 2016-08-25 | 2018-03-01 | 大江生醫股份有限公司 | 香蕉發酵物、其製造方法及用途 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014075745A1 (en) * | 2012-11-19 | 2014-05-22 | Université Catholique de Louvain | Use of akkermansia for treating metabolic disorders |
US10793907B2 (en) * | 2014-10-21 | 2020-10-06 | Psomagen, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions |
EP3783010A1 (en) * | 2015-05-06 | 2021-02-24 | Wageningen Universiteit | Method of culturing akkermansia |
CN104886495A (zh) * | 2015-06-23 | 2015-09-09 | 云南省玉溪市香蕉研究所 | 益生菌发酵香蕉果泥的制备方法 |
US10426811B2 (en) * | 2016-08-25 | 2019-10-01 | Tci Co., Ltd. | Banana fermentation product and manufacturing method and use of the same |
CN109355349B (zh) * | 2018-11-30 | 2021-03-26 | 江南大学 | 一种阿克曼氏菌特异性筛选培养基及其制备方法和应用 |
CN109810931A (zh) * | 2019-04-03 | 2019-05-28 | 广州康泽医疗科技有限公司 | 一种培养嗜黏蛋白阿克曼氏菌的培养基及其使用方法 |
-
2019
- 2019-07-22 TW TW108125874A patent/TWI719549B/zh active
- 2019-08-02 CN CN201910714710.3A patent/CN112274577B/zh active Active
- 2019-12-26 US US16/727,389 patent/US11478525B2/en active Active
-
2020
- 2020-01-28 MY MYPI2020000474A patent/MY196168A/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103599059A (zh) * | 2013-11-06 | 2014-02-26 | 曹书林 | 一种香蕉组合物发酵类美容美体膏 |
TW201807193A (zh) * | 2016-08-25 | 2018-03-01 | 大江生醫股份有限公司 | 香蕉發酵物、其製造方法及用途 |
Non-Patent Citations (4)
Title |
---|
方圆圆等: "不同益生菌干预对高脂饮食诱导肥胖小鼠脂代谢及脂多糖影响的研究", 《中国实验诊断学》 * |
沈男等: "嗜黏蛋白阿克曼氏菌及其在肥胖机制中的研究进展", 《基础医学与临床》 * |
葛晓龙等: "粪菌移植改善肥胖和糖尿病病人的研究进展", 《肠外与肠内营养》 * |
赵立平等: "《微生物组学与精准医学》", 31 December 2017, 上海交通大学出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116548609A (zh) * | 2022-01-27 | 2023-08-08 | 大江生医股份有限公司 | 益生质组合物及其用途 |
Also Published As
Publication number | Publication date |
---|---|
TWI719549B (zh) | 2021-02-21 |
MY196168A (en) | 2023-03-17 |
US20210023159A1 (en) | 2021-01-28 |
TW202104583A (zh) | 2021-02-01 |
US11478525B2 (en) | 2022-10-25 |
CN112274577B (zh) | 2022-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW202045036A (zh) | 包含降低血糖之乳酸菌菌株之食品組合物以及醫藥組合物之用途 | |
CN105018408B (zh) | 一种在培养基中添加芦丁促进益生菌生长的方法 | |
CN114854643A (zh) | 一种促进乳杆菌和双歧杆菌协同增殖的培养基及其应用 | |
KR20160138056A (ko) | 부티르산 산생균 및 그 이용 | |
CN104642870A (zh) | 一种益生元组合物 | |
JP2018153182A (ja) | ラクトバチルスプランタルムtci378、およびそれを用いた脂肪の減少および胃腸機能の改善における使用 | |
CN112274577B (zh) | 包含芭蕉属物种发酵物的组合物的用途及益生质组合物 | |
JP2007507214A (ja) | プレバイオティック効果の分析 | |
KR20220099914A (ko) | 유해균 억제를 통한 프로바이오틱스 활성화용 조성물 | |
CN109315769A (zh) | 一种用于改善人体肠内环境的组合物及其制备方法 | |
Niu et al. | Effect of fructooligosaccharides on the colonization of Lactobacillus rhamnosus AS 1.2466 T in the gut of mice | |
JP4248985B2 (ja) | ラクトバシラス・ファーメンタム、それと担体からなる肥満症または糖尿病の予防・治療用製剤、食品組成物 | |
JP5082048B2 (ja) | 免疫賦活作用及び/又はアレルギー抑制作用を有し、且つ胃液耐性を有する新規乳酸菌 | |
JP6301024B2 (ja) | フィーカリバクテリウム属細菌増殖剤 | |
CN108795823B (zh) | 一种改善女性孕产妇肠道菌群的益生菌的培养方法和应用 | |
CN114680171A (zh) | 一种调节肠道健康的发酵乳及其制备方法 | |
CN119193391A (zh) | 一种具有降血糖能力的植物乳植杆菌Lp116及其应用、产品与方法 | |
CN113209141A (zh) | 一种基于褐藻提取物与罗伊氏乳杆菌的组合物及其应用 | |
CN112616932A (zh) | 保护口腔健康的羊奶片及其制备方法 | |
Levantovsky et al. | Nutritional requirements of bifidobacteria | |
CN112322531A (zh) | 一种高活性嗜酸乳杆菌冻干粉的生产方法及应用 | |
JP2015198638A (ja) | ビフィズス菌醗酵方法及び増殖方法 | |
Paliy et al. | Influence of various prebiotic components on the main growth indicators of probiotic bacteria | |
CN118516248B (zh) | 一株缓解司美格鲁肽不良作用的动物双歧杆菌乳亚种bx-186 | |
WO2022085456A1 (ja) | 炎症性腸疾患用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |